Can a pill tame stubborn hand eczema?
NCT ID NCT05682859
First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time
Summary
This trial tests whether an oral medication called roflumilast can reduce the severity of chronic hand eczema in adults. Participants with moderate to severe hand eczema will receive either roflumilast or a placebo for 16 weeks, followed by a period where everyone gets the active drug. The main goal is to see if at least 75% improvement in eczema severity is achieved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- roflumilast (an oral PDE4 inhibitor)
- What this could lead to
- If effective, roflumilast could offer a new oral treatment option for people with chronic hand eczema that doesn't respond to topical therapies.
- What could go wrong
- This is a small, phase 4 trial, so results may not apply broadly. Roflumilast can cause side effects like nausea, diarrhea, and weight loss.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HAND ECZEMA are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of dermatology and veneorology, Bispebjerg Hospital
Copenhagen, 2400, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- 2000 patients to be tracked in largest-ever hand eczema registry
- New ointment shows promise for stubborn hand eczema
- New cream could soothe stubborn hand eczema in teens
- Scientists seek skin samples to unlock secrets of common rashes
- Scientists probe skin secrets to unlock eczema mysteries
- New hope for stubborn hand eczema: drug targets inflammation from within